Ask AI
ProCE Banner Activity

Experts Discuss Cases and Questions in Contemporary CLL Treatment

Clinical Thought

In this commentary derived from a live symposium at ASCO 2026, experts discuss current treatment paradigms for patients with CLL and answer HCP questions, with a focus on cases in previously untreated and relapsed/refractory disease.

Released: July 13, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, and Lilly.

AstraZeneca

BeOne Medicines

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This educational activity is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for individuals with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Support patient engagement in care for CLL/SLL through effective shared decision-making and communication strategies

  • Compare the mechanisms of action and clinical rationales for novel targeted therapies that are approved vs under investigation for management of CLL/SLL

  • Recommend individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with CLL/SLL in alignment with patient preferences, clinical evidence, and expert recommendations

  • Assess the clinical implications of emerging efficacy and safety data for novel targeted and cellular therapies on treatment sequencing in CLL/SLL

  • Apply best practices for biomarker testing before treatment initiation and at disease progression to guide optimal therapy selection and sequencing in patients with CLL/SLL

Financial Disclosures

Primary Author

Catherine C. Coombs, MD: consultant/advisor/speaker: AbbVie, Allogene, AstraZeneca, BeOne, Genentech, Janssen, Johnson & Johnson, Lilly, Octapharma, Pharmacyclics; researcher: AbbVie, BeOne, Carna, Lilly.

Nitin Jain, MD: researcher: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Pharmacyclics, Precision Biosciences, Sana Biotechnology, Takeda, Triarm, Ubix; consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB.

Nicole Lamanna, MD: consultant/advisor: AbbVie, AstraZeneca, BeOne, Lilly/Loxo; researcher (paid to institution): AbbVie, AstraZeneca, BeOne, Lilly/Loxo, Genentech, Genmab, Octapharma, Oncternal.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.